Current Strategies to Improve Engraftment in Cord Blood Transplantation

Robert Danby1-3* and Vanderson Rocha1-3

1Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK
2NHS Blood and Transplant, Oxford Centre, John Radcliffe Hospital, Oxford, UK
3Eurocord, Hôpital Saint Louis APHP, University Paris VII IJH Paris, France

Abstract

Umbilical cord blood (UCB) remains an important alternative source of hematopoietic stem cells (HSC) for allogeneic transplantation when suitable HLA-matched donors are unavailable. Cord blood (CB) offers many benefits including rapid availability, absence of risk to the donor, and a low incidence of graft-versus-host disease. However, although the overall survival of patients receiving unrelated CB transplants is comparable to using other HSC sources, UCB transplantation is associated with delayed engraftment and poor immune reconstitution, particularly in adults. While this is partly due to the lower cell dose in UCB grafts, it may also reflect the relative immaturity of cord blood. Therefore, many different strategies to enhance hematopoietic engraftment following UCB transplantation are currently under investigation. This article will review the latest techniques including improved collection, HLA-matching, homing and expansion of CB, and the use of double CB grafts, third-party donors, and accessory cells. As many of these methods are now in clinical trials, it is anticipated that UCB transplantation will continue to improve, further expanding our understanding of CB biology and HSC transplantation.

Keywords: Umbilical cord blood; Hematopoietic stem cell transplantation; Engraftment; Neutrophil recovery; Platelet recovery

Introduction

Allogeneic hematopoietic stem cell (HSC) transplantation is a potential curative therapy for many hematological conditions, particularly malignant disorders such as leukemia and lymphoma. Following conditioning with chemotherapy and/or radiotherapy, the transfer of HSC from a healthy donor into the immunosuppressed recipient generates new hematopoiesis, rescuing the host from severe prolonged aplasia. Long-term cure can then be achieved through the development of an immune mediated graft-versus-tumor (GvT) response, formed by the new donor-derived immune system.

HSC for allogeneic transplantation are usually obtained from a healthy sibling or unrelated donor, matched for the major class I (A, B, and C) and class II (DRB1, DQ1) human leukocyte antigens (HLA) (10/10 match). The availability and choice of donor is primarily determined by the size of the family and the HLA-type of the recipient. Since any full sibling has only a one-in-four chance of being HLA-matched at all loci, only around 30% of all potential transplant recipients have a suitable HLA-matched sibling donor [1,2]. For the remainder, an HLA-allele matched unrelated donor may be found through national and international volunteer unrelated donor registries, including over 23 million donors currently on the Bone Marrow Donors Worldwide (BMDW) database [3]. However, certain ethnic groups or HLA-types are relatively under-represented in these registries and some populations have a greater diversity of HLA-types [2]. Therefore, if unrelated HSC donors cannot be found, alternative donor sources can be considered, including umbilical cord blood (UCB), HLA-mismatched unrelated donors or haploidentical family members.

UCB is an established alternative source of HSC for allogeneic transplantation with over 30 000 UCB transplants having been performed worldwide [1,4]. Due to the relative immaturity of cord blood (CB), the lower immunogenicity of UCB grafts, and the lower incidence of graft-versus-host disease (GvHD) compared to bone marrow (BM) and peripheral blood stem cell (PBSC) transplants, less stringent HLA-matching has traditionally been required [5-7]. Until recently, only HLA matching at HLA-A and HLA-B (serological) and HLA-DRB1 (allelic) were commonly used, with mismatches at one or two loci usually tolerated if sufficient cell doses were transplanted [8]. With over 600 000 frozen UCB units stored in cord blood banks worldwide, unrelated UCB transplantation is now an option for many patients that lack a suitable HLA-matched sibling or unrelated donor [1]. UCB also has the advantage of being immediately available, avoiding further delays to transplantation, and without any associated risks to the donor [1].

While UCB has increased the applicability of HSC transplantation, UCB transplantation has previously been associated with high rates of graft failure, delayed engraftment, poor immune reconstitution, and increased risk of opportunistic infection [6,7,9-11]. This is partly due to lower cell dose since each CB unit (CBU) contains a one to two log lower total cell dose compared to BM and PBSC harvests (PBSCH) [12]. However, the biological properties of CB and the relative immaturity of CB cells may also be a factor. UCB CD34+ cells have a more immature phenotype and CB immune cells (T-, B-, natural killer (NK), and dendritic cells) are antigen inexperienced (naïve), being less responsive to allogeneic stimulation and producing lower levels of effector cytokines [13-15].

Within this article, the main factors influencing hematopoietic recovery following UCB transplantation will be discussed. This review will summarize the latest results of current strategies being used to improve engraftment, including improved collection, HLA-matching.
homing and expansion of CB, and the use of double CB grafts, third-party donors, and accessory cells (Table 1).

Biology of HSC Engraftment

Following conditioning therapy (chemotherapy and/or Total Body Irradiation (TBI)), the CB graft (s) is intravenously infused into the recipient. The CB cells pass through the recipient’s circulation to the BM microvasculature, where a highly regulated process of adhesion and migration allows homing of HSC and early hematopoietic progenitor cells (HPC) to the BM niche. In mouse models, only around 10% of intravenously infused HSC actually reach the BM, the rest being sequestered in the lung, liver, and spleen [16-17]. Within the BM sinusoids, cell adhesion molecules (CAM), particularly P- and E-selectin, allow adhesion and rolling of the HSC along the endothelial walls [18]. Additional cell-to-cell interactions, using the integrins CD49d/CD29, CD44/CD29, and CD11a/CD18, are then required for firm adhesion of the HSC to the endothelium and migration across the endothelial layer and basal membrane into the BM microenvironment [18,19]. Transient inhibition of vascular endothelial cadherin (VE-cadherin, CD144) by CD34+ HSC may also enhance migration by impairing tight adherens junctions between endothelial cells, increasing sinusoidal permeability [20]. The HSC migrate to the paratrabecular niche where they engraft, proliferate, and differentiate into full hematopoiesis. Over time, the number of HSC in the paratrabecular regions gradually falls as the corresponding number of cells in the highly vascular central region expands [21].

Homming, migration and engraftment of HSC to the BM are highly dependent upon chemotactic signals. Stromal Cell-Derived Factor-1 (SDF-1) (chemokine (C-X-C motif) ligand 12 (CXCL12)) is arguably the most important chemo-attractor for HSC engraftment, although other proteins, such as CXCL10 (IP-10), CCL2 (MCP-1), and SCF may also have a role [22-24]. SDF-1 levels, produced by BM stroma (endothelium and endosteum), are increased following conditioning therapy and the infused HSC follow the SDF-1 gradient towards the BM [25]. SDF-1 binds to its receptor, CXCR4 (fusin/CD124), on the surface of HSC, activating a series of second messenger pathways including guanine triphosphatases (GTPase) and phosphatidylinositol-3-kinase (PI3K) [18,24]. These signals increase expression of the integrins CD49/CD29 and CD11a/CD18 and induce cytoskeletal changes required for adhesion and migration of HSC across the endothelium [26]. Several factors also increase the sensitivity of CXCR4 on HSC to SDF-1, including complement (C3a), hyaluronic acid, VCAM-1, fibrinogen, and thrombin. Once engrafted, SDF-1 may also promote HSC proliferation and survival [27,28].

In comparison to BM and PBSC harvests, there are important biological differences in CB that may influence hematopoietic recovery. CB contains a higher proportion of HSC and granulocyte-macrophage progenitor cells within the CD34+ fraction [29]. However, CB CD34+ cells have a less mature phenotype with a higher frequency of primitive CD34+CD38− multipotent progenitors but lower proportions of committed progenitors [30,31]. CB CD34+ cells have a greater proliferative and repopulating capacity in both in vitro and in vivo studies [32-35]. Gene expression profiling and transcriptional analysis of CD34+ cells from UCB and BM also shows differential expression of genes involved in adhesion, proliferation, differentiation, apoptosis, and engraftment [36-38]. There are also differences in the number, composition, and maturity of other cell populations within CB, including T-cells, NK-cells, regulatory T-cells, and dendritic cells [13-15,39]. Therefore, delayed hematopoietic recovery after UCB transplantation may be due to the immaturity of CB HSC, needing more cell divisions before differentiating to mature progenitors, or due to the lack of other cell populations that facilitate engraftment [6].

Engraftment following UCB Transplantation

Following infusion of the CB graft, there is an initial period of aplasia during which the BM HSC engraft, proliferate, and differentiate. In UCB transplantation (UCBT), the time to neutrophil recovery (first of three consecutive days with a neutrophil count >0.5 × 109/l) is longer than with other sources of HSC, with a median time of approximately 26-30 days for UCB, 21 days for BM, and 14 days for PBSC [5-8,40,41]. Platelet recovery is also longer with a median time to engraftment (first of three consecutive days with an unsupported platelet count >20 × 109/l) in UCBT ranging from 50-100 days. Graft failure is also higher following UCBT at around 10% to 30% [4,6-10,41,42]. As a consequence, UCBT has a significant risk of infection-related morbidity and mortality. In a retrospective analysis of infectious complications in 35 consecutive double UCBT for high-risk hematological disease, there were 99 infectious events, 77 of which occurred within the first 100 days post-transplant [41]. There were 34 confirmed severe bacterial infections in 19 patients with a 30-day cumulative incidence of first infection of 43% (95% Confidence Intervals (CI), 35-51%). 21 of these infections were gram-positive bacteria and the remainder gram-negative bacilli. The 100-day cumulative incidence of first bacterial infection was 55% (95% CI, 47-63%). In addition, there were 14 fungal infections in 12 patients with a 30-day cumulative incidence of 12% (95% CI, 10-14%). Nine were invasive aspergillosis and three were candida septicaemia. The Eurocord group also retrospectively analyzed infections in 510 UCBT’s performed between 1994 and 2001 (unpublished study, V Rocha personal communication). 75% recipients were children and 78% had
malignant disorders. All received single CBU using myeloablative conditioning and 85% received Anti-Thymocyte Globulin (ATG). The cumulative incidence of neutrophil recovery was 75% and non-relapse mortality (NRM) by day 100 was 32%. There were 686 episodes of severe infection in 352 patients within the first 100 days post-UCBT. Of these, 404 were bacterial (gram-positive 277, gram-negative 122, others five) in 290 patients; 189 were viral (142 cytomegalovirus, 21 adenovirus, 12 Epstein-Barr virus, seven human herpes virus-6, seven others) in 164 patients; 54 were fungal (26 candida, 20 aspergillus, eight others) in 53 patients; five were toxoplasmosis in five patients; 34 were of unknown origin in 31 patients. The cumulative incidence of first severe infection by day 100 was 69% (49% for bacterial, 32% for viral, 10% for fungal and 1% for toxoplasmosis). In multivariate analysis, long time to engraftment was independently associated with the incidence of overall infection (Hazard Ratio (HR) 3.34, P<0.001), bacterial infection (HR 4.54, P <0.001), viral infection (HR2.50, P<0.001), and fungal infection (HR 5.88, P=0.02). Shortening the time to engraftment may therefore decrease the incidence of infections after UCBT, possibly reducing morbidity and mortality.

Infection is a major contributing cause in 25% to 45% of deaths post-UCBT, particularly within the first three months post-transplant [4,6,9,41]. In a Grupo Español de Trasplante Hematopoyético (GETH) study of 192 consecutive adult unrelated allogeneic hematopoetic stem cell transplants (HSCT), the 100-day and 3-year infection-related mortality (IRM) for UCBT (n=48) was 30% (95% CI 10-40%) and 40% (95% CI 12-58%) respectively [43]. However, although infection remains a major concern, it is still unclear whether UCBT has a significantly higher proportion of deaths due to infection compared to other forms of HSCT. In an International Bone Marrow Transplant Registry (IBMTR) comparison of unrelated donor transplants for leukemia, Laughlin and colleagues reported the proportion of deaths due to infection within 100 days at 45%, 21%, and 24% for UCB (n=150), HLA-matched marrow (n=367), and HLA-mismatched marrow (n=83) respectively (P=0.01) [10]. However, Rocha and colleagues (2004) observed that a similar proportion of transplant deaths were due to infection when comparing CB (42%) to unrelated BM (41%) [7]. In the Spanish GETH study, although UCBT had a higher risk of severe infection compared to BM/PBSC transplants (85% vs 69%, P<0.01), the 100-day IRM (30% vs 28% vs 22%, P=0.2) and 3-year IRM (40% vs 42% vs 38%, P=0.5) were not significantly different [43]. Likewise, in a study of serious infections in the two years post-transplant in 136 pediatric myeloablative conditioning (MAC) unrelated donor transplants, the cumulative incidence of one or more infections was not significantly different between BM (81%), T-cell depleted BM (83%), or UCB (90%) (P=0.12). In multivariate analysis of all infections, there was no significant difference between BM and UCB (Relative Risk (RR) 1.0, P=0.84). The proportion of patients in which infection was a causal or contributing factor towards death was also not significantly different (BM 36%, T-cell depleted BM 33%, UCB 30%) [44]. Therefore, although UCBT is associated with delayed engraftment compared to BM and PBSC transplants, it appears that a similar proportion of deaths are due to infection for all three HSC sources. This may be due to the higher rates of GVHD and subsequent immunosuppression and infections seen with BM and PBSC transplants. Improved strategies to reduce infection-related mortality for all forms of allogeneic HSCT are therefore required.

Main Factors Influencing UCB Engraftment

**Cell dose and HLA-match**

Seminal publications in the late 1990s established that the probability of UCBT engraftment and the time to neutrophil recovery were significantly associated with cell dose (Total Nucleated Cells (TNC) or CD34+ cells per recipient weight) and the degree of HLA-matching (HLA-A and -B (antigen), HLA-DRB1 (allelic)) [5,9]. Subsequent retrospective series further demonstrated the importance of cell dose and the interaction with the number of HLA-disparities. In a Eurocord study of 550 UCBT, the number of HLA-mismatches and the TNC dose at freezing were significantly associated with neutrophil recovery [45]. Furthermore, neutrophil engraftment showed a linear relationship with the number of HLA-disparities. The cumulative incidence of neutrophil recovery by day 60 ranged from 83% for HLA-matched UCBT to 53% for 3/6 HLA-mismatched UCBT. In a CIBMTR review of 503 pediatric UCBT and 282 BM transplants, the incidence of neutrophil and platelet engraftment was similar for BM and HLA-matched (6/6) UCBT [46]. However, UCB matched at only 5/6 or 4/6 HLA-loci had lower probabilities of neutrophil and platelet recovery, although higher TNC doses (>3 × 107/kg) for the 5/6 HLA-matched UCBT was associated with improved platelet recovery. In light of these findings, in 2009, Eurocord published recommendations for the selection of CBUs [8]. When a single unit (6/6 or 5/6 HLA-matched) contained insufficient cells (TNC<2.5 × 107/kg upon freezing, 2.0 × 107/kg on thawing), double UCBT was recommended, aiming for a combined TNC dose>3.0 × 107/kg. Higher doses were proposed if the UCB was only 4/6 HLA-matched (TNC>3.5 × 107/kg upon freezing, ≥2.5 × 107/kg on thawing) and CBUs with three or more HLA-mismatches were not routinely recommended.

In 2010, Barker and colleagues further characterized the interaction between cell dose and HLA-matching in a retrospective analysis of 1061 MAC single UCBT in patients with leukemia or myelodysplasia [47]. The cumulative incidence of neutrophil engraftment by day 77 was 74% (95% CI, 71-77%) and platelet engraftment (>50 × 109/l) 46% (95% CI 43-49%) by nine months post-transplant. TNC dose was associated with neutrophil and platelet engraftment in a dose-responsive manner. Using a TNC dose of 2.5-4.9 × 107/kg as the reference group, the HR for neutrophil engraftment were (i) TNC 0.7-2.4 × 107/kg: 0.7 (95% CI 0.6-0.8), P<0.001; (ii) TNC 5.0-9.9 × 107/kg: 1.2 (95% CI 1.0-1.5), P<0.001; (iii) TNC>10.0 × 107/kg: 1.8 (95% CI 1.3-2.5), P<0.001. Comparable results were observed with platelet engraftment. Similarly, HLA-matching was also associated with neutrophil and platelet engraftment in a progressive manner, although no significant difference was observed in neutrophil recovery between UCBT with one and two HLA-matches. Using the 5/6 HLA-match as the reference group, the HR for neutrophil engraftment were (i) Matched (6/6): 1.8 (95% CI 1.3-2.5), P<0.001; (ii) 4/6 HLA-match: 1.0 (95% CI 0.9-1.2), P=0.90; (iii) 3/6 HLA-match: 0.8 (95% CI 0.6-1.1), P=0.16. There were 130 deaths due to graft failure with TNC dose, center experience, and year of transplantation independently associated with these events. Analyzing the interaction between TNC dose and HLA-matching (reference group was CBU with 5/6 HLA-match and TNC 2.5-5.0 × 107/kg) on engraftment, transplant related mortality (TRM), and overall mortality demonstrated that the best outcome was for matched UCBT (6/6) irrespective of TNC. UCBT using CBU with a 5/6 HLA-match and TNC>2.5 × 107/kg or 4/6 HLA-match and TNC>5.0 × 107/kg were next. Of note, using CBUs with a 4/6 HLA-match and TNC>5.0 × 107/kg had faster engraftment than CBU with a 5/6 HLA-match and TNC dose>2.5 × 107/kg although there was no significant difference in survival. Transplants using CBU with a 4/6 HLA-match and TNC>2.5 × 107/kg had higher mortality, followed by CBU with a 4-5/6 HLA-match and TNC<2.5 × 107/kg or a 3/6-HLA match. As a result of these findings, it was recommended that when selecting CBUs, priority should be given to HLA-matched units,
followed by single HLA-mismatched units with TNC>2.5 × 10^7/kg or two HLA-mismatches with TNC>5.0 × 10^7/kg.

While many of these studies retrospectively analyzed the outcomes of UCBT using CB type for HLA-A and -B (antigen) and HLA-DRB1 (allelic), the importance of enhanced HLA-matching strategies had increasingly been recognized. Eapen and colleagues (2011) retrospectively analyzed the impact of HLA-typing at HLA-A, -B, and -C (intermediate resolution) and HLA-DRB1 (allelic) on 803 single UCBT for acute leukemia (n=727) or myelodysplasia (n=76) [48]. Neutrophil recovery at day 28 was significantly lower for transplants mismatched at three/four HLA-loci (matched 70% (95% CI 57-79%); one mismatch 64% (95% CI 55-71%); two mismatches 64% (95% CI 57-69%); three mismatches 54% (95% CI 48-60%); four mismatches 44% (95% CI 32-55%)). More specifically, mismatching at HLA-DRB1 in the presence of mismatches at any other two HLA-loci and mismatching at HLA-A in the presence of mismatches at three or four HLA-loci were associated with inferior neutrophil engraftment. TNC was R=0.56 (95% CI 0.43-0.69), P=0.000, or mismatched at two (n=5; 3.27 (95% CI 1.42-7.54), P=0.006), three (n=5; 3.34 (95% CI, 1.45-7.71), P=0.005), or four loci (n=75; 3.51 (95% CI, 1.44-8.58), P=0.006) compared to matched units (n=69; HR 1.00). In addition, TRM using CBU mismatched at HLA-C was greater compared to fully matched CBU (8/8) (HR 3.97 (95% CI, 1.27-12.40), P=0.02). Additional matching at HLA-C was therefore recommended.

The impact of high resolution HLA-typing on engraftment has also been examined. In 2005, a retrospective analysis of high resolution typing at HLA-A, -B, -C, -DR, and -DQ from 122 UCBT, did not demonstrate any association between the number of HLA-mismatches and neutrophil recovery. High-resolution mismatches at HLA-A in the direction of rejection were associated with reduced engraftment by day 60 (87% v 65%, P=0.04). However, overall, there appeared to be little benefit from the additional high resolution typing [49]. Delaney et al. [50] reviewed high resolution typing (HLA-A, -B, -C, -DR, -DQ) in 53 reduced intensity conditioned (RIC) double UCBT. Neutrophil and platelet recovery were significantly faster in those UCBT with allelic matching at HLA-B, although there was no effect seen with HLA-A, -C, and -DQ. However, this study was not sufficiently powered to allow a direct comparison between using the standard or high-resolution HLA-matching strategies. Recently, in a joint CIBMTR and Eurocord analysis, Eapen et al. [51], analyzed the effect of high resolution typing on the outcomes of 1658 MAC single UCBT for hematological malignancy. Neutrophil recovery by day 28 was significantly lower for transplants mismatched (MM) at three or more alleles compared to fully matched CBU (Odds Ratio (OR) 0.56 (95% CI 0.36-0.88) P=0.01; OR 0.55 (95% CI 0.34-0.88) P=0.01; OR 0.45 (95% CI 0.25-0.82), P=0.009 for three, four, and five MM respectively). UCBT performed with mismatches at three or more alleles had inferior neutrophil recovery compared to transplants mismatched at one or two alleles only (3/4 MM OR 0.69 (95% CI, 0.55-0.86), P=0.001; 5 MM or more 0.56, (95% CI, 0.35-0.89), P=0.00). However there were no significant differences in recovery observed when considering mismatching at specific HLA loci. In this series, non-relapse mortality was also significantly associated with the degree of HLA-mismatch with the lowest risk observed in those transplants matched at the allelic level at HLA-A, -B, -C, and -DRB1. Single HLA-mismatches at HLA-A, -C, or -DRB1 were associated with increased NRM (HR 3.05 (95% CI, 1.52-6.14), P=0.02; HR 3.04 (95% CI, 1.28-7.20), P=0.01; HR 2.93 (95% CI, 1.38-6.25), P=0.005 respectively). Importantly, using CBU with TNC>3.0 × 10^7/kg was associated with significantly higher NRM, independent of HLA-matching. However, compared to CBU containing TNC>3.0 × 10^7/kg, further increases in cell dose was not associated with a significantly lower NRM. Taken altogether, Eapen et al. [51] therefore proposed that single UCBT must have a minimum pre-cryopreserved TNC of 3.0 × 10^7/kg. The best HLA-allele matched CBU should then be selected, although mismatches at one or two alleles are acceptable. However, CBU with mismatches at three or more alleles should only be used with caution due to the higher rates of graft failure and NRM.

For non-malignant conditions, the interaction between cell dose and HLA-matching remains less clear due to the different biology in these disorders, the effects of previous treatment, and the relative paucity of data compared to studies on hematological malignancies. Patients with chemotherapy naive conditions, e.g. hemoglobinopathies, have a more functional immune system prior to transplantation, while heavily pre-transfused recipients are more likely to have HLA-antibodies. In a Eurocord analysis of 270 single UCBT for non-malignant conditions (BM failure 40%, primary immunodeficiency 36%, metabolic disorder 24%), neutrophil and platelet engraftment were associated with cell dose [8]. HLA-matching was also important with a significant difference in engraftment between CBU matched at 5-6/6 HLA loci compared to ≤ 4/6 loci (P=0.046). Increasing cell dose, except when CBU were mismatched at three or more loci, reduced the impact of HLA-mismatch. Therefore in 2009, Eurocord recommended that for non-malignant conditions, CBUs with higher cell doses should be selected [8]. In particular, for CBUs matched at 4/6 HLA-loci, the recommended minimum cell dose was 4.0-5.0 × 10^7/kg at collection and 3.5 × 10^7/kg at infusion. CBUs with three or more HLA-mismatches were not recommended. Further studies in UCBT for non-malignant conditions are required, particularly given the recent findings regarding the impact of cell dose and high-resolution typing in malignant disorders.

CBU cell dose and HLA-matching clearly have important implications for engraftment and mortality following UCBT. However, the minimum cell dose required and CB selection criteria remain under much debate, especially given that these recommendations are based upon retrospective analyses. Whether priority should be given to TNC dose or HLA-matching or whether increasing the minimum TNC dose from 2.5 × 10^7/kg to 3.0 × 10^7/kg improves UCBT outcomes will need to be determined in future studies. While improving outcomes, it is also important to ensure that CB selection criteria maintain the availability of UCBT to those patients that otherwise lack a suitable donor.

**Conditioning and GvHD prophylaxis**

The intensity and type of conditioning can influence the rate of engraftment following HSC transplantation [52]. HSC transplant conditioning has two roles; the first is myeloablation i.e. reducing the recipient's own hematopoiesis, decreasing residual tumor burden, and emptying the BM niche for the incoming graft. The second is immunosuppression i.e. reducing rejection, either of the graft by the host immunity (Host-versus-Graft (HvG)) or of the host by the incoming donor graft (Graft-versus-Host (GvH)). The extent to which any conditioning regimen contains these two components can be manipulated, depending on the recipient, the disease being treated, and the risk of rejection. Over the last decade, use of reduced intensity conditioning (RIC) regimens has increased in all forms of allogeneic HSCT, including pediatric and adult UCBT [53,54]. RIC regimens are less myeloablative but provide sufficient immunosuppression to allow donor engraftment. Disease eradication is then dependent upon the donor-derived T-cells recognizing residual tumor as 'non-self', producing an immune mediated Graft-versus-Tumor (GvT) response.
Importantly, RIC regimens have lower toxicity, shorter periods of aplasia and reduced TRM, allowing HSCT to be performed in older patients and in those with significant co-morbidities.

In 2003, Barker and colleagues reported the results of 43 RIC UCBT using Fludarabine (200 mg/m²), TBI (200 cGy) and Busulphan (8 mg/kg) (Bu/Flu/TBI) or Cyclophosphamide (50 mg/kg) (Cy/Flu/ TBI) [56,57]. The median cell dose was 3.7 × 10⁹/kg and the UCB grafts (93%) were 1-2 HLA antigen-mismatched. The cumulative incidence of sustained donor engraftment was 76% (95% CI, 56-96%) for Bu/Flu/TBI recipients and 94% (95% CI, 84-100%) for Cy/Flu/TBI recipients (P<0.01). The median day of neutrophil recovery was 26 days (range, 12-30 days) and 9.5 days (range, 5-28 days) for the Bu/Flu/TBI and Cy/Flu/TBI recipients respectively. The cumulative incidence of platelet engraftment (>20 × 10⁹/l) by day 180 was 24% (95% CI, 6-42%) for Bu/Flu/TBI recipients and 80% (95% CI, 57-100%) for Cy/Flu/TBI recipients (P<0.01). Using this approach, Brunstein et al. [58] published a larger series of 110 UCBT using the Flu/Cy/TBI RIC regimen and ciclosporin/ mycophenolate mofetil (MMF) GvHD prophylaxis. Neutrophil recovery by day 42 was 92% with a median time to recovery of 26 days (range, 12-42 days) for Bu/Flu/TBI recipients and 94% (95% CI, 84-100%) for Cy/Flu/TBI recipients (P<0.01). 

The GITMO 2008 protocol, using standard methods [75] showed a calcineurin inhibitor (Ciclosporin or Tacrolimus) with MMF or steroids. However, intensive administration of mycophenolate (1000 mg t.d.s. compared to 17.5 mg/kg b.d.) post-UCBT has been associated with delayed neutrophil recovery (median 22 days (range, 14-41 days) v 17 days (range, 14-48 days), P=0.02) [73]. Furthermore, a recent combined GETH and Gruppo Italiano Trapianto Midollo Osseo (GITMO) study analyzed the results from 227 MAC single UCBT using Busulphan/Thiotepa/Fludarabine/ATG with ciclosporin and steroids (GETH 2005 protocol, n=88) or ciclosporin and mycophenolate motefil (GITMO 2008 protocol, n=145) [74]. Of note, the GITMO 2008 protocol also had a slight reduction in the ATG dose (2 mg/kg/ day days -4 to -2 vs. days -5 to -2). The cumulative incidence of myeloid engraftment at day 60 was 94% (95% CI, 88-99%) and 88% (95% CI, 82-93%) respectively, with a median time to recovery of 19 and 23 days (P<0.0001). There was no significant difference in platelet recovery by day 180 (81% (95% CI, 72-89%) v 73% (95% CI, 66-80%), P=0.60). As recognized by the authors, this was a non-randomized study using an historical group (GETH2005) with slight differences in minimum cell dose requirements and ATG dose. Nevertheless, these observations, suggest that mycophenolate may have an adverse effect on myeloid engraftment and continued review of GVHD prophylaxis is required to improve CB engraftment.

Strategies to Improve Engraftment

Increasing cell dose

Improved collection, processing and storage: CBU are collected through sterile puncture and drainage of the umbilical cord immediately after delivery. However, many HPC/HSC remain in the placental vessels, with potentially as many HPC remaining in the placenta as are collected using standard methods [75]. Collection from the placental vessels and/or placental perfusion can, therefore, increase cell yields. However, it remains to be determined whether these methods are practical for routine CB collection and without increasing contamination from maternal cells [75]. Validated and standardized operating procedures
for processing CB and cryopreservation are necessary to maximize cell recovery and ensure reliability between different cord blood banks. Immediate processing and/or storage of CB at 4°C are associated with higher post-thaw recovery and greater viability than storage at room temperature [76]. Furthermore, in vivo engraftment in mouse models was significantly impaired with CB stored at room temperature for 72 hours prior to processing. Use of modern automated systems for red cell depletion and volume reduction have also improved CB processing, although there is still an associated cell loss (TNC recovery 78.8% ± 7.3% for Sepax (n=670); 76.8% ± 7.5% for APX (n=1000)) [77]. Furthermore, cryopreservation, thawing, and washing CB also causes a further 20% cell loss [78]. Therefore minimizing CB processing and improving good manufacturing compliant methods to enhance cell recovery could increase the number of cells available for infusion.

**Double cord blood transplantation:** If a single CBU cannot provide the recommended cell dose for transplantation (TNC or CD34+ cells), two CBUs from different donors can be infused, one after the other. Double cord blood transplantation was first reported in 2001 by the Minneapolis group when attempting to increase the cell dose given to adults and larger children [79]. Both units contribute to early engraftment, although eventually, one unit predominates [53]. In an analysis of 23 double UCBT following MAC, hematopoiesis was observed from a single donor in 76% patients at day 21 and 100% patients by day 100 [80]. Likewise, in 81 patients with sustained chimerism after receiving a double UCBT using a non-myeloablative regimen, single donor chimerism was detectable in 57%, 81%, and 100% patients at day 21, 100, and 365 respectively [53]. Double UCBT show high rates of engraftment (85% to 100%) with the median time to neutrophil engraftment ranging from 9 to 33 days depending on the conditioning regimen and/or the use of GCSF [53,81,82]. Interestingly though, a significant difference in the cumulative incidence and rate of engraftment has not been demonstrated between patients receiving one or two CBUs [42,53,54,83]. As the double UCBT patients tend to be heavier, this would suggest an initial booster effect from the non- engrafting unit [84]. However, the incidence of grade II-IV acute GVHD appears to be higher in patients receiving double UCBT [42,85]. Similarly, a lower relapse risk has also been reported in patients receiving two CBUs for acute leukemia, possibly through an enhanced graft-versus-leukemia response [83].

Ruggeri et al. [41] reported the outcomes of 35 double UCBT in recipients with high-risk hematological diseases. The cumulative incidence of neutrophil recovery at day 60 was 72% ± 8% (86% for malignant disorders) with a median time of 25 days (range, 11-42 days). The median time to platelet recovery was 50 days (range 28-152 days) with a cumulative incidence at day 180 of 54% ± 10%. The incidence of acute GVHD was 47% with an estimated overall survival of 48% at two years. More recently, in long-term follow-up of the 135 double UCBT in patients with hematological malignancies reported to the SGGM-TC registry, the cumulative incidence of neutrophil engraftment by day 60 was 91% and 3-year overall survival 41% [86]. Ruggeri et al. [42] then reported a Eurocord and EBMT comparison of single and double UCBT using MAC in adults with acute leukemia. The cumulative incidence of neutrophil engraftment by day 60 was not significantly different between the single and double UCBT (82% ± 6% vs 90% ± 6% respectively, P=NS). However, in multivariate analysis, TNC>3.2 × 10^7/kg was independently associated with higher neutrophil engraftment (HR 0.63 (95% CI, 0.36-0.86), P=0.01). Double UCBT had higher rates of grade II-IV acute GVHD although there was no difference in relapse. Leukemia Free Survival (LFS) was 43% ± 3% at two years’ post-UCBT. With appropriate conditioning and sufficient cell dose, the overall results between single and double UCBT appear similar.

**Cord blood expansion:** *Ex vivo* cord blood expansion increases the number of HSC for long-term engraftment as well as enhancing the number of committed progenitors to attenuate the initial period of aplasia. The expanded CBU can then be given alone or in combination with an unmanipulated unit. The expanded unit improves early hematopoietic recovery but it is the unmanipulated unit that usually provides long-term engraftment [87]. UCB expansion has been achieved using several methods. In liquid culture, isolated CD34+ or CD133+ HSC are expanded in the presence of selected cytokines and growth factors, including stem cell factor (SCF), Thrombopoietin (TPO), Granulocyte Colony Stimulating Factor (GCSF), and/or fms-like tyrosine kinase 3 ligand (FLT-3-L) [88,89]. The optimal milieu of cytokines and growth factors remains uncertain but several groups have shown improved expansion by the addition if IL-3 and/or IL-6 [90]. Shpall et al. [88] performed a feasibility study in which CD34+ cells were isolated from a fraction (40-60%) of the UCB unit and expanded in liquid culture with SCF, GCSF, TPO, and megakaryocyte growth and differentiation factor. The remainder of the unit was infused with the expanded cells following myeloablative conditioning. The median TNC dose infused was 0.99 × 10^7/kg and the median time to engraftment was 28 days (range, 15-49 days) for neutrophils and 106 days (range, 38-345 days) for platelets. Using a modification to this approach, a phase I/II trial was performed in which CD133+ cells were isolated from a portion of the CBU and expanded in liquid cultures with SCF, FLT-3-L, IL-6, TPO, and the copper chelator TEPA [91]. The median TNC fold expansion was 219 (range, 2-260). Both expanded and unexpanded cells were infused, achieving a median TNC of 1.8 × 10^7/kg. Nine of the ten patients engrafted with a median time to neutrophil and platelet engraftment of 30 days (range, 16-46 days) and 48 days (range, 35-105 days) respectively. Delaney et al. [92] later reported results from a phase I trial using an immobilized Notch ligand delta-1 in addition to SCF, FLT-3-L, TPO, IL-3, and IL-6. Ten patients with high-risk leukemia were treated with a myeloablative double UCBT in which one unit was expanded using this protocol. The average fold expansion was 562 (range, 146-1496) for TNC and 164 (range 41-471) for CD34+ cells. Nine of the ten patients engrafted with a median time to neutrophil engraftment of 16 days (range, 7-34 days). However, in contrast to other studies, there was predominance for donor CD33+ and CD14+ cell engraftment from the expanded unit. The second expansion method uses co-culture with a supporting network of Mesenchymal stromal cells to provide a hematopoietic microenvironment that supports HSC proliferation [93]. De Lima et al. [87] reported the results of 31 patients receiving two UCB units, one of which was expanded *ex vivo* with mesenchymal stem cells (MSC). This *ex vivo* culture system expanded TNC and CD34+ cells by a median factor of 12.2 and 30.1 respectively and the median TNC dose infused was 8.34 × 10^7/kg. Of the 24 patients that received *ex vivo* expanded cells, 23 achieved neutrophil engraftment, at a median time of 15 days (range, 9-42 days), and 18 had sustained platelet engraftment, at a median time of 42 days (range, 15-62 days). Both compared favorably to 80 CHIMTR historical controls that received unmanipulated double UCBT only (neutrophil engraftment 24 days (range, 12-52 days), P<0.001; platelet engraftment 49 days (range, 18-264 days), P=0.03). Although the expanded CBU improved early hematopoietic recovery, in all cases, the unmanipulated unit provided long-term engraftment. Finally, HSC expansion has also been achieved using a continuous perfusion culture system in which cells are supplied with fresh culture media and gaseous exchange [94,95]. In a phase I study, Jaroscak et al. [94] expanded a portion of an UCB unit using a continuous perfusion culture device and infused...
these expanded cells 12 days after the remainder of the original unit. The median fold increase in TNC was 2.4 (range, 1.0-8.5). 21 of the 26 patients attained neutrophil engraftment with a median time of 22 days (range, 13-40 days). The median time for platelet engraftment was 71 days (range, 39-139 days; n=16).

Although CB expansion appears promising, it remains to be determined if these strategies will enhance engraftment and improve clinical outcomes following UCBT. Furthermore, it needs to be established whether the increase in committed progenitors is at the expanse of long term HSC. There are many ongoing prospective clinical trials of CB expansion that will hopefully answer these questions, as well as looking at the cost effectiveness and practicality of such approaches [96]. The MD Anderson Cancer Centre are currently performing a phase I/II study to evaluate the safety and feasibility of transplantation using UCB expanded with MSC in patients with hematological malignancies (ClinicalTrials.gov NCT00498316). Similarly, a multicenter, randomized study to evaluate double UCBT with one of the CBUs expanded using MPC (Mesoblast) is recruiting (ClinicalTrials.gov NCT01854567). The Fred Hutchinson Cancer Centre has a multicenter randomized study of MAC double UCBT with or without infusion of off-the-shelf ex vivo expanded cryopreserved CB progenitor cells in hematological malignancies (ClinicalTrials.gov NCT01690520). Several studies are also using NiCord ex vivo expanded UCB. A safety and efficacy study of transplanting a single NiCord expanded CBU in patients with hematological malignancies is recruiting, while a similar study in double UCBT (one expanded CBU) has recently closed (ClinicalTrials.gov NCT01816230; NCT01221857) (Table 2).

Combined use of umbilical cord blood with third party donor: Sebrango et al. [97] reported the results of 55 combined UCB/ haploidentical transplants for high risk myeloablative and lymphoproliferative disorders. Patients received MAC followed by CB (median TNC 2.39 × 10^7/kg (range, 1.14-4.30); median CD34+ 0.11 × 10^3/kg (range, 0.04-0.37)) and positively selected CD34+ and/ or CD133+ cells (median 2.4 × 10^3/kg (range, 1.05-3.34)) from a third-party haploidentical donor. Using this approach, the haploidentical graft provides early engraftment but it is the CB that provides long-term engraftment. The maximum cumulative incidence of neutrophil and platelet engraftment was 96% and 78% with a median time to recovery of 10 and 32 days respectively. Full UCB chimerism was achieved in 50 patients (91% (95% CI, 84-99%)) with a median time of 57 days (range, 11-186 days). Liu et al. [98] transplanted 45 patients using a RIC regimen (Fludarabine/Melphalan/ATG) with an unrelated UCB graft and CD34+ selected cells from a haploidential family member. The cumulative incidence of neutrophil engraftment was 95% at day 50 with a median time to recovery of 11 days. The cumulative incidence of platelet engraftment was 83% at day 100 with a median time to recovery of 19 days. The median percentage of PB cells of UCB origin was 10%, 78%, and 95% at day 30, 100, and 180 respectively. Conversely, the median percentage of PB cells from the haploidential graft was 86%, 22%, and 2% at the corresponding times. The cumulative incidence of acute and chronic GvHD was 25% and 5% respectively, with NRM at one year 38%, relapse 30%, and overall survival 55%. Interestingly, in this study the CB dose had no impact on time to hematopoietic recovery. It was therefore hypothesized that CB selection should be focused upon improved HLA-matching, potentially improving long-term outcomes. Recently, Chen et al. [99] reported a prospective study of 50 patients with hematological malignancy given a MAC combined UCB/Haploidential transplant. However, in contrast to the previous studies, the haploidential grafts were T-replete, with all surviving patients achieving sustained haploidential engraftment (three had mixed chimerism). 48 patients engrafted within 20 days with a median time to neutrophil recovery of 13 days (range, 11-20 days) and platelet recovery of 15 days (range, 11-180 days). Other clinical outcomes such as GvHD were reportedly better than historical controls. Taken together, these studies highlight the possible benefits of combining UCB and haploidential grafts. However, which graft eventually provides long-term hematopoiesis appears to be dependent upon using T-cell depletion of the haploidential graft. Further prospective studies will be needed to determine whether either of these approaches significantly improves engraftment and other transplant-related outcomes compared to UCBT alone. Several groups have ongoing phase II/III studies comparing double UCBT with a combined haploidential/UCB approach in hematological disease (ClinicalTrials.gov NCT01050964; NCT01745913; NCT00943800).

Additional considerations for HLA-matching

While an HLA-matched CBU, with sufficient cell dose, remains the ideal choice, this is not always feasible. Therefore, consideration of other factors such as the direction of the HLA-mismatch and the detection of HLA-antibodies may be important. If a recipient is homozygous at an HLA-locus but the donor heterozygous at the same site (one antigen/allele matching the recipient), there is a mismatch in the host-versus-graft (HvG) direction (i.e. risk of rejection). Conversely, if the donor is homozygous but the recipient heterozygous at the same HLA-locus (one antigen/allele matching the donor), the mismatch is in the graft-versus-host (GvH) direction. When a mismatched antigen/allele is present in the recipient and donor, the mismatch is bidirectional. In 2011, Stevens and colleagues analyzed the implications of HLA-mismatch direction in 1202 single UCBT [100]. 890 transplants had bidirectional HLA-mismatches, 58 GvH-mismatches only, 40 HvG-mismatches only and 145 had other combinations. Recipients of HvG-mismatches only had a trend towards lower myeloid engraftment compared to those with a single bidirectional mismatch (HR 0.7 (95% CI, 0.4-1.1), P=0.1). Conversely, those with no HLA-mismatches or HvG-mismatches only had improved engraftment (HR 1.5 (95% CI, 1.2-2.0), P=0.003 respectively). In subgroup analysis of those with hematological malignancies, recipients of CBU with HLA-mismatches in the GvH direction only also had lower treatment failure (HR 0.5 (95% CI, 0.3-0.9), P=0.02) and lower overall

<table>
<thead>
<tr>
<th>Main focus of clinical study</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Using CB for specific hematological disorders</td>
<td>22</td>
</tr>
<tr>
<td>Conditioning regimen</td>
<td>22</td>
</tr>
<tr>
<td>Use of cellular therapy (e.g. T-cells) post-CB transplantation</td>
<td>9</td>
</tr>
<tr>
<td>Use of expanded CBU</td>
<td>9</td>
</tr>
<tr>
<td>Combined use of CB and Haploidential grafts</td>
<td>7</td>
</tr>
<tr>
<td>Use of unlicensed CBUs</td>
<td>5</td>
</tr>
<tr>
<td>Direct intra-bone infusion of CB</td>
<td>4</td>
</tr>
<tr>
<td>Combined use of two CBUs</td>
<td>3</td>
</tr>
<tr>
<td>Co-infusion of CBU with accessory cells (MSC/Tregs)</td>
<td>3</td>
</tr>
<tr>
<td>Use of growth factors (Eltrombopag) post-UCB transplantation</td>
<td>3</td>
</tr>
<tr>
<td>UCB vs. Haploidential transplantation</td>
<td>2</td>
</tr>
<tr>
<td>Improved homing of UCB HSC</td>
<td>2</td>
</tr>
<tr>
<td>T-cell depletion of CBU</td>
<td>2</td>
</tr>
<tr>
<td>Fucosylation of CB HSC</td>
<td>1</td>
</tr>
<tr>
<td>Management of GvHD infection post-CB transplantation</td>
<td>2</td>
</tr>
<tr>
<td>Total clinical trials</td>
<td>96</td>
</tr>
</tbody>
</table>

Table 2: Current clinical trials in cord blood transplantation. Summary of the current clinical trials in unrelated cord blood transplantation for hematological conditions that are currently recruiting as registered with ClinicalTrials.gov (12/01/2014). (CB: Cord Blood; CBU: Cord Blood Unit; MSC: Mesenchymal Stem Cells; Tregs: Regulatory T-cells; GvHD: Graft-versus-host Disease).
mortality (HR 0.5 (95% CI, 0.3-0.9), P=0.02). In a similar Japanese study of 2977 single UCBT, recipients of CBU with HLA-mismatches in the GvH direction only showed a trend towards improved neutrophil and platelet recovery compared to single bidirectional mismatched transplants (HR 1.18 (95% CI 0.98-1.42); P=0.08; HR 1.23 (95% CI 1.00-1.51); P=0.05 respectively) [101]. However, in a recent Eurocord analysis of 1669 single UCBT, neutrophil and platelet recovery showed no significant difference between these corresponding groups [102]. Furthermore, in these later two studies, HLA-mismatches (one or two) in either direction were not associated with significant differences in overall mortality or survival. Therefore, although possibly influencing engraftment, the recently published data does not show that the direction of HLA-mismatch has a significant impact on overall survival after UCBT. As such, selection of CBU based upon the direction of HLA-mismatch is not routinely recommended.

In contrast, the detection of anti-HLA donor specific antibodies (DSA) should be considered. In a retrospective analysis of 386 MAC single UCBT for hematological malignancy, 89 patients had anti-HLA antibodies, of which 20 had specificity against the CBU [103]. In multivariate analysis, neutrophil and platelet recovery were significantly worse in these 20 patients compared to the antibody negative group (RR 0.23 (95% CI, 0.09-0.56), P=0.001; RR 0.31 (95% CI, 0.12-0.81), P=0.02 respectively). Similar findings were demonstrated in 73 double UCBT where the presence of DSA was associated with increased graft failure (5.5% v 18.2% v 57.1% for none, single, or dual DSA positivity; P=0.0001) and longer neutrophil recovery (median 29 days (any DSA) v 21 days (no DSA), P=0.04). The presence of DSA was also associated with inferior three-year survival (0.0% v 45.0%, P=0.04) [104]. More recently, a retrospective Eurocord analysis on the impact of DSA in 294 RIC UCBT was performed. 21% recipients had anti-HLA antibodies of which 14 (5%) had donor specificity. Day 60 neutrophil engraftment (44% v 81%, P=0.006) and one year TRM (46% v 32%, P=0.06) were inferior in the presence of DSA. In light of these observations, it is recommended that recipients should be screened for anti-HLA antibodies before transplant and only CBU’s selected that do not have the specificity of the anti-HLA antibodies.

The implication of NK-cell alloreactivity for CB engraftment remains less clear. NK-cell alloreactivity derives from a mismatch between the inhibitory receptors for self-MHC class I molecules on NK cells (killer cell Immunoglobulin like Receptors (KIR)) and MHC class I antigens on recipient cells [105]. In haploidentical HSC transplantation, KIR-ligand incompatibility in the GvH direction has been associated with reduced graft failure, GvHD, relapse, and improved survival [105-107]. In a Eurocord analysis of 218 single UCBT for acute leukemia, KIR ligand incompatibility in the GvH direction was not associated with the cumulative incidence of neutrophil recovery [108]. However, it was independently associated with reduced relapse (HR 0.53 (95% CI, 0.3-0.99), P=0.05) and improved overall survival (HR 2.0 (95% CI, 1.2-3.2), P=0.004). In contrast, the Minnesota group showed no effect of KIR mismatch on TRM, relapse, or survival in MAC UCB transplants [109]. Furthermore, in the RIC UCBT subset, KIR mismatch was associated with worse GVHD, TRM, and survival. The impact on engraftment was not specifically analyzed. In a more recent analysis of 80 double UCBTs, engraftment did not differ between groups receiving transplants from KIR ligand-compatible or incompatible donors. The median time to recovery of neutrophils and platelets was 21 days (P=0.3) and 42 days (P=0.95) in both groups respectively [110]. There was no significant effect on relapse, PFS, or OS. In keeping with these findings, Tanaka and colleagues (2013) found no association between KIR ligand-incompatibility in the GVH direction and the incidence of GvHD, relapse, NRM, and overall survival in single UCBT without ATG [111]. However, in multivariate analysis, engraftment was significantly lower in the acute lymphoblastic leukemia subset when a KIR incompatibility was present in the HvG direction (HR 0.66 (95% CI, 0.47-0.91), P=0.01). Overall, the available data does not currently support the routine use of KIR matching in the selection of CBU. However, further studies are warranted particularly for assessing the impact of HvG KIR incompatibility on engraftment.

**Improving delivery and homing of HSC**

To overcome the potential hurdles with homing of HSC to the BM niche and/or sequestration within other organs, direct intrabone infusion of CB has been proposed. In animal models, intrabone injection of BM and CB was associated with greater seeding efficiency, long-term maintenance of donor hematopoiesis and significantly higher long-term survival [112,113]. In a phase I/II study, 32 consecutive patients with acute leukemia received an UCBT using intrabone infusion [114]. No complications occurred during administration. The median time to neutrophil and platelet recovery was 23 days (range, 14-44 days; n=28) and 36 days (range, 16-64 days; n=27) respectively and all engrafted patients showed full donor chimerism from day 60. 16 patients were alive and in remission with a median follow-up of 13 months. Okada et al. [115] demonstrated in a phase I study that intrabone infusion of unwashed cord blood following a RIC regimen was also well tolerated. In 10 patients, there were no injection related complications and the median time to neutrophil recovery was 17 days. Saglio et al. [116] also showed that intrabone injection was also well tolerated in children. In a recent Eurocord retrospective analysis of single unit intrabone UCBT (n=87) with double unit intravenous UCBT (n=149), intrabone infusion was associated with improved neutrophil engraftment by day 30 (76% v 62%, P=0.01) and improved platelet engraftment by day 180 (74% v 64%, P=0.003). In multivariate analysis adjusting for differences between the groups, intrabone UCBT had improved neutrophil recovery by day 30 (HR 1.5 (95% CI, 1.04-2.17, P=0.03) and greater platelet recovery by day 180 (HR 1.97 (95% CI, 1.35-2.9, P=0.004) compared to intravenous UCBT. Intrabone infusion was also associated with a lower incidence of acute GvHD and showed a trend towards improved disease-free survival (DFS) [117]. Although not a prospective randomized trial, these results are clearly still encouraging. Further phase II non-randomized clinical trials are ongoing to evaluate graft kinetics and immune reconstitution following intrabone infusion of cord blood cells in hematological malignancies (ClinicalTrials.gov NCT00886522; NCT01332006; NCT01613066; NCT01717788).

**Ex vivo priming of UCB with agents that promote migration and homing of HSC to the BM microenvironment may also enhance engraftment** [118,119]. In mouse models, inhibition of the membrane bound extracellular peptide dipeptidyl peptidase-4 (DPP4) (CD26), which cleaves SDF-1, enhances long-term engraftment in UCB CD34+ cells in NOD/SCID/beta 2 microglobulin null mice [120,121]. Alternatively, fucosylation (the addition of a fucose) of ligands expressed on HSC may enhance engraftment. Fucosylation of UCB HSC (CD34+CD38low cells) is required for interaction with P- and E-selectin expressed in the BM microvasculature. Treatment of UCB HSC with Guanosine Diphosphate (GDP) fucose and exogenous alpha 1-3 fucosyl transferase VI improved adhesion and rolling of the cells on P- and E-selectin under flow conditions. It also improved human HSC engraftment in irradiated NOD/SCID mice [18,122]. In NOD-SCID interleukin-2Ry (null) mice, Robinson et al. [123] also demonstrated that only fucosylated UCB CD34+ were responsible for engraftment...
and that ex vivo fucosylation improved UCB engraftment rates. These pre-clinical studies show interesting results and, as such, further investigation is warranted to determine whether these techniques can improve HSC engraftment in a cost-effective way and without adversely affecting long-term results. A multicenter, non-randomized phase II trial of inhibition of CD26 peptidase using Sitagliptin to enhance engraftment after UCBT in adults with hematological malignancy is currently in process (ClinicalTrials.gov NCT01720264). Similarly, the MD Anderson group is recruiting to a non-randomized phase II study of CB fucosylation to enhance homing and engraftment in patients with hematological malignancies (ClinicalTrials.gov NCT01471067).

**Growth factors**

Although many UCBT protocols use in vivo recombinant granulocyte colony stimulating factor (G-CSF) to aid myeloid engraftment, relatively little published data has formerly examined its effect. In 102 MAC single UCBT, use of G-CSF was associated with a trend (P=0.09) towards improved neutrophil recovery. The cumulative incidence of neutrophil recovery by day 42 was 90% (95% CI 84-97%) with a median of 21 days (range, 9-54 days) for G-CSF treated patients compared to 80% (95% CI 60-100%) with median of 31 days (range, 17-45 days) for no G-CSF. However, use of G-CSF did not remain significant in multivariate analysis. In a larger study in 2004, Gluckman et al. [124] analyzed 550 UCBT’s in patients with hematological malignancy in which G-CSF was given to 60% of patients. As well as cell dose and HLA-matching, early use of G-CSF was independently associated with improved neutrophil recovery (HR 1.66 (95% CI, 1.34-2.05), P<0.0001). There have also been occasional case reports on the successful use of combined G-CSF and recombinant in vivo stem cell factor (SCF) post-UCBT. However, further studies will be required to determine if there is any benefit to this approach. In relation to platelet recovery, there remains much interest in the use of thrombopoietin agonists to improve engraftment. Thrombopoietin (TPO) is produced by the liver and kidneys and regulates the production of platelets by stimulating megakaryocyte production and differentiation within the bone marrow. It also has an important role in regulation and proliferation of HSC and other multipotent HPC and has been used in ex vivo expansion of CB [89,125-127]. Although phase II/III clinical trials of recombinant TPO in thrombocytopenic disorders produced disappointing results due to the development of TPO specific antibodies, there have been more interesting results with peptide mimetics (Romiplostim) and non-peptide small molecule TPO receptor (c-Mpl) agonists (Eltrombopag) [128-130]. In NOD/SCID mouse xeno transplant models, Eltrombopag increased the expansion of human UCB CD34+, CD45+, and CD41+ cells with an associated increase in PB platelets and white cells [131]. A phase I study of Eltrombopag in HSCT (non-UCB) has shown good safety and tolerability [132]. Consequently, there are now several early phase trials of Eltrombopag currently recruiting in both adult and pediatric UCBT (ClinicalTrials.gov NCT01927731; NCT01757715; NCT019406562).

**Co-transplantation of accessory cells**

**Mesenchymal stem cells:** Mesenchymal stem cells (MSC) are multipotent undifferentiated stromal cells with capacity to self-renew and/or differentiate into mesenchymal cells including chondrocytes, osteocytes, adipocytes, cardiomyocytes, and neurons. They are present in PB, BM, UCB, and non-hematopoietic tissues including fat, muscle, and UC connective tissue, e.g. Wharton’s jelly, although their exact function in vivo remains unclear. MSC are a heterogeneous population that lack hematopoietic markers (CD45/CD34/CD14) but express the antigens SH-3/SH-4 (CD73), Thy-1 (CD90), and Endoglin (CD105) [133]. However, there is considerable phenotypic variation between MSC obtained from different sources and there is no single unifying marker allowing specific isolation of these cells. MSC have low immunogenicity and potent immunosuppressive function that may be useful for improving engraftment and preventing GvHD. They do not express class II MHC molecules or co-stimulatory molecules and, thus, do not elicit allo-antigenic responses. They can also suppress T and NK-cell proliferation, cytokine secretion, and B-cell function [134-136]. Functional mechanisms include cell-contact dependent and independent responses including IL-10, TGFβ, nitric oxide (NO), and induction of regulatory T cells [136-138].

In relation to UCBT, pre-clinical murine studies demonstrated that co-transplantation of MSC with CB CD34+ cells in NOD/SCID mice improved engraftment [139-141]. In addition, UC MSC support ex vivo expansion of CB HSC in long-term cultures [142]. In 2009, MacMillan and colleagues performed a phase I/II study of ex vivo expanded haploidentical BM-derived MSC in pediatric patients with leukemia receiving a MAC unrelated UCBT [143]. Eight patients received MSC (median dose 2.1 × 10⁹/kg (range, 0.9-5.0)) in addition to UCB (median TNC 3.1 × 10⁹/kg (range, 2.0-12.4)), with three patients receiving an additional infusion of MSC on day 21. There were no harmful side effects related to infusion of the MSC. All patients achieved neutrophil engraftment at a median time 19 days (range, 9-28 days). Six patients achieved platelet engraftment at a median of 53 days (range, 36-98 days). Rates of engraftment, GvHD, and survival were comparable to equivalent historical group demonstrating the safety and feasibility of this approach. In a similar pilot study, nine patients received a MAC UCBT with co-infusion of BM-derived MSC and T-depleted HSC from a third party donor [144]. All patients achieved neutrophil engraftment with a median time to recovery of 12 days (range, 10-31 days) and full CB chimerism at a median of 51 days (range, 20-186 days). The maximum cumulative incidence of platelet engraftment was 88% (95% CI, 70-100%) at a median of 32 days (range, 13-97 days). However, there was no difference in the rate of engraftment compared to a control group of 46 transplants from the same center not receiving MSC. Bernardo et al. [145] reported similar findings in 13 pediatric UCB transplants using paternal MSC with no difference in engraftment or rates of rejection compared to 39 matched historical controls. Recently, phase I/II study of UCB transplants with UC-derived MSC has been performed [146]. Five patients received ex vivo expanded MSC obtained from Wharton’s jelly without any adverse events. Neutrophil engraftment (median 11 days (range, 7-13 days)) and platelet engraftment (median 32 days (range, 22-41 days)) were significantly faster than in nine control patients not receiving MSC. These early studies demonstrate that co-infusion of MSC with UCBT can be performed safely. However, the full implications for engraftment and immune reconstitution still remain unclear and further prospective studies are required.

**Regulatory T cells:** The human immune system maintains the delicate equilibrium between protecting the body from harmful pathogens (‘non-self’) while being unresponsive to self-antigens (‘self-tolerance’). This is achieved through passive central tolerance (‘positive’ and ‘negative’ selection of T-cells in the thymus) and peripheral immune tolerance in which specific cells (‘suppressor cells’) suppress autoreactive clones using dominant mechanisms. Of these, regulatory T cells (Tregs) are the best described. In 1995, Sakaguchi et al. [147] identified a population of CD4+ T cells expressing the IL-2 receptor alpha chain (CD25). When CD4+CD25+ cells, isolated from BALB/c nu/nu mice, were transferred into BALB/b nu/nu mice, they induced a widespread autoimmune disease, which could be prevented by the co-transfer of donor CD4+CD25+ cells. The CD4+CD25+ T-cells
became known as Tregs and, in 2001, human CD4+CD25+ Tregs were first described [148,149]. In 2003, the transcription factor forkhead box P3 (Foxp3) was found to be specifically expressed in Tregs and is now thought to be the master regulator of Treg differentiation and function [150,151]. Tregs exert their immune tolerance by inhibiting proliferation and cytokine secretion of T, B, NK, NK-T, and antigen presenting cells. Proposed functional mechanisms include cell contact independent mechanisms, such as sequestration of IL-2 and production of inhibitory cytokines (IL-10, IL-35), and cell contact dependent mechanisms, including CTLA-4, cell surface TGFβ, and granzyme mediated apoptosis [152].

There has been particular interest in Tregs in the setting of allogeneic HSCT. In mice, co-transfer (1:1) of CD4+CD25+ Tregs with CD4+CD25- effector T cells from C57BL/6 mice into MHC mismatched BALB/c mice prevented the lethal GvHD seen with the transfer of CD4+CD25 effector T cells alone [153]. Furthermore, CD4+CD25+ Tregs co-transferred with CD4+CD25 conventional T cells to an MHC mismatched mouse with leukemia were able to prevent GvHD but did not prevent an effective GvT response [154]. In human allogeneic HSCT, reduced numbers of CD4+CD25+ cells, CD4+FOXP3+ cells, CD4+CD25+FOXP3+ cells, or FOXP3 mRNA in blood and tissues have been observed in patients with GvHD [155-160]. Similarly, low numbers of CD4+FOXP3+ Tregs in PBSC was an independent predictor of acute GvHD in MAC transplants [161,162]. A low graft CD3/Treg ratio (<36) in MAC T-replete PBSC transplants was also found to be an independent predictor of improved NRM and overall survival [163,164]. UCB also contains CD4+CD25+ Tregs with the proportion of cells inversely correlating with gestational age up to the levels found in adult PB (2% to 5% of CD4+ T cells) [165]. In contrast to adult PB, the majority of CB Tregs expresses naïve markers and does not initially show suppressor activity [166,167]. However, upon antigenic stimulation, these cells upregulate CD25, CTLA-4, and FOXP3, proliferating with a higher expansion capacity compared to adult Tregs and possess potent suppressive activity [166,167].

In light of these observations, using Tregs in allogeneic HSCT may be a promising strategy to promote engraftment and immune reconstitution and prevent GvHD. Two clinical trials of adoptive transfer of ex-vivo isolated Tregs have been performed in humans. The first was a phase I study in which patients with a high risk of relapse were pre-emptively given up to 5 x 10^5/kg Tregs prior to donor lymphocyte infusions [168]. In nine patients, there were no adverse events related to the Tregs. In the second study, 28 HLA-haploidentical transplants were given 2-4 x 10^7/kg isolated Tregs (50% FOXP3+; four days prior to receiving CD34+ cells and 0.5-2.0 x 10^6/kg conventional T cells [169]. The administration of Tregs into a lymphopenic environment was to allow pre-activation and homeostatic expansion of Tregs in vivo [170]. Despite the absence of other immunosuppression, only two patients developed grade II-IV acute GvHD. In the context of UCBT, Treg isolation has been more problematic due to the low TNC number per CBU. Therefore, in vitro expansion is necessary in which Tregs are expanded using anti-CD3/CD28 stimulation and IL-2. The mTOR inhibitor, Rapamycin, may enhance Treg expansion further by preventing proliferation of conventional T cells whilst allowing expansion of Tregs [171-173]. To date, only Brunstein et al. [174] have reported results using expanded human Tregs. 23 double UCBT patients were given Tregs at a dose of 1-30 x 10^5/kg on day one, with 13 of these receiving an additional dose of 30 x 10^5/kg on day 15. Tregs were obtained by CD25 bead isolation from third party UCB and expanded with CD3/CD28 beads and IL-2 (300 IU/ml) for 18 days. There were no reported adverse events. The cumulative incidence of sustained neutrophil engraftment was 87% (95% CI, 70-97%) and the incidence of platelet recovery by day 100 was 74% (95% CI, 51-97%) at a median of 46 days (range, 27-87 days). When compared with 108 historical controls, donor engraftment was not adversely affected by the co-infusion of Tregs, although the study was not designed to show improved engraftment. These reports are, therefore, the first tentative steps toward Treg cellular therapies and highlight the feasibility of such approaches. The effect of Tregs on UCB engraftment remains to be elucidated. However, Fujisaki et al. [175] demonstrated in mouse models using high resolution in-vivo imaging, that allogeneic HSC co-localize with Foxp3(+) Tregs on the endothelial surface of the bone, potentially forming an immune privileged site for engraftment. Furthermore, depletion of Tregs resulted in loss of the allogeneic HSC. Continued research into the impact of Tregs on UCBT and engraftment is therefore required.

Conclusion

In recent years, UCB has remained an important source of HSC for those patients requiring HSC transplantation but lacking a suitable sibling or unrelated donor. As our combined knowledge and experience of UCB transplantation has steadily increased, clinical outcomes after UCB transplantation have continued to advance. In particular, the incidence and speed of UCB engraftment has improved, mainly due to the use of higher cell doses, improved HLA-matching, better supportive care and greater center experience. However, as our basic understanding of CB biology, HSCs, and hematopoiesis progresses, further clinical improvements can be made. New strategies such as CB expansion, improved homing and delivery of CB HSC, and use of third-party supportive cells all show promising developments in early trials. Prospective clinical studies are in progress to ascertain whether these techniques will further enhance engraftment and determine what impact this will have on morbidity and mortality following UCBT. Combined with new methods to improve immune reconstitution, it is anticipated that, for specific patients, UCB transplantation will continue to have a crucial role in the management of hematological disorders.

Acknowledgements

The authors would like to thank NHS Blood and Transplant (UK) and the National Institute for Health Research (NIHR) Biomedical Research Centre for their support.

References


